The PCR-based test, run on Roche's Liat platform, was among several other assays that was cleared by the agency last month.
With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
The assay runs on the Panther Fusion system, which combines transcription-mediated amplification, real-time TMA, and real-time PCR with full sample-to-result automation.
The firm intends to use the net proceeds of the offering and available cash to retire its remaining convertible notes when they become callable.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.
Amid a flat month for the index, some firms saw large swings in their stock price. Natera led the gainers, while NantHealth led the decliners.
The company credited its molecular diagnostics and international businesses as drivers of new growth.
Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.
The firm said that its Panther Fusion system expands molecular testing capabilities, and increases productivity and flexibility for labs.